Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Lifted by Logos Global Management LP

Logos Global Management LP grew its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 27.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,800,000 shares of the company’s stock after buying an additional 600,000 shares during the quarter. Logos Global Management LP owned approximately 3.98% of Trevi Therapeutics worth $8,344,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new position in Trevi Therapeutics during the first quarter valued at approximately $47,000. Hsbc Holdings PLC bought a new position in Trevi Therapeutics in the second quarter valued at about $61,000. American Century Companies Inc. increased its stake in shares of Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after acquiring an additional 7,902 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in Trevi Therapeutics in the 1st quarter worth $208,000. Finally, Dimensional Fund Advisors LP lifted its stake in Trevi Therapeutics by 217.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after acquiring an additional 49,475 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Insider Buying and Selling

In related news, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $644,205.26. The sale was disclosed in a filing with the SEC, which is available through this link. In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at $644,205.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares of the company’s stock, valued at $608,069.40. The disclosure for this sale can be found here. Insiders sold a total of 40,355 shares of company stock worth $116,663 in the last ninety days. 24.37% of the stock is owned by insiders.

Trevi Therapeutics Stock Performance

TRVI opened at $3.30 on Tuesday. The firm has a market cap of $232.44 million, a P/E ratio of -9.71 and a beta of 0.96. Trevi Therapeutics, Inc. has a 52-week low of $0.97 and a 52-week high of $4.00. The business’s fifty day moving average is $3.00 and its 200-day moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the prior year, the business earned ($0.07) earnings per share. On average, research analysts predict that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Rodman & Renshaw began coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $7.00 price target on the stock. Raymond James began coverage on Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target on the stock. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Finally, Leerink Partners began coverage on Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $7.67.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.